UBS Cuts Estimates and Price Target on InterMune (ITMN); Don't Expect Clarity Until '13
Tweet Send to a FriendGet Alerts ITMN Hot Sheet
Price: $9.58 -3.82%
Rating Summary:
11 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Rating Summary:
11 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Trade ITMN Now!
UBS maintains a 'Neutral' on InterMune Inc. (NASDAQ: ITMN) price target of $10.50 (from $13.50).
Analyst, Matthew Harrison, reports three key points from the company's conference call: (1) Management believes the weak rev growth was driven by high discontinuations (~30% vs 20% annually) due to pts with aggressive disease making up more of the initial pt pop and dropping off sooner than mild/mod points. Also a greater loss of point during titration contributed. (2) Mgt. now believes 1/3 of starter packs are NOT used by new pts, so adj. new pt. adds are 350 (4Q11), 300 (1Q12) and 400 (2Q12). (3) Mgt. expects higher priced countries to trend toward the German price over a few years.
Harrison doesn't see little in the way of upside catalysts, and therefore believes the stock will trade on quarterly revenues for the rest of 2012, which he doesn't expect will excite investors. (FY12 loss lowered from (3.00) to (3.25) and FY13 from (2.59) to (2.94))
For an analyst ratings summary and ratings history on InterMune Inc. click here. For more ratings news on InterMune Inc. click here.
Shares of InterMune Inc. closed at $9.91 yesterday, with a 52 week range of $9.66-$36.96.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Matthew Harrison, reports three key points from the company's conference call: (1) Management believes the weak rev growth was driven by high discontinuations (~30% vs 20% annually) due to pts with aggressive disease making up more of the initial pt pop and dropping off sooner than mild/mod points. Also a greater loss of point during titration contributed. (2) Mgt. now believes 1/3 of starter packs are NOT used by new pts, so adj. new pt. adds are 350 (4Q11), 300 (1Q12) and 400 (2Q12). (3) Mgt. expects higher priced countries to trend toward the German price over a few years.
Harrison doesn't see little in the way of upside catalysts, and therefore believes the stock will trade on quarterly revenues for the rest of 2012, which he doesn't expect will excite investors. (FY12 loss lowered from (3.00) to (3.25) and FY13 from (2.59) to (2.94))
For an analyst ratings summary and ratings history on InterMune Inc. click here. For more ratings news on InterMune Inc. click here.
Shares of InterMune Inc. closed at $9.91 yesterday, with a 52 week range of $9.66-$36.96.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Jefferies Bumps Zumiez (ZUMZ) Numbers Up, But Remains on Sidelines
- Toll Bros. (TOL) Estimates/PT Raised at Compass Point
- Deutsche Bank Adjusts Dean Foods (DF) Price Target to $13
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT ChangeRelated Entities
UBS
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
